Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057837 · ClinicalTrials.gov registry record · Phase 2
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT00057837 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 140 participants.
The verdict
NCT00057837, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating extensive-stage small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have extensive-stage small cell lung cancer.
Interventions
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Irinotecan
- DRUG Topotecan
- BIOLOGICAL G-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2004-07-14 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057837
The ClinicalTrials.gov registry entry for NCT00057837 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00057837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057837 about?
NCT00057837 is a clinical study titled "Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating extensive-stage small cell lung can...
What is the current status of trial NCT00057837?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2004-07-14. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00057837?
The interventions under investigation include: Cisplatin (DRUG), Etoposide (DRUG), Irinotecan (DRUG), Topotecan (DRUG), G-CSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT00057837?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.